Cystic Fibrosis

Cystic fibrosis is a life threatening, inherited disease of the exocrine glands. The condition primarily affects the digestive and respiratory systems which become clogged with a thick, sticky mucus. Cystic fibrosis is caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which results in an excess of salt and water passing into cells, causing a thick, sticky mucus to build up in bodily passageways.

Cystic Fibrosis (CF)

Cystic fibrosis is a genetic condition that affects the production and flow of mucus within the lungs and digestive system, parts of the body that then become clogged with a thick, sticky mucus.

Cystic Fibrosis Causes

Cystic Fibrosis Symptoms

Cystic Fibrosis Diagnosis

Cystic Fibrosis Treatment

Genetics of Cystic Fibrosis

Cystic Fibrosis Screening

Cystic Fibrosis Questions

Coping With Cystic Fibrosis

Cystic Fibrosis Facts

Cystic Fibrosis Epidemiology

Cystic Fibrosis Prognosis

See more featured articles »

Cystic Fibrosis Research

Could CRISPR Repair CFTR in Cystic Fibrosis Patients?

Sweat Test for Cystic Fibrosis

Cystic Fibrosis and Salty Skin

Cystic Fibrosis Evolution

Lung Transplantation for Cystic Fibrosis

Gene Therapy as a Potential Cure for Cystic Fibrosis

Cystic Fibrosis and Infertility

Cystic Fibrosis History

Tests for Cystic Fibrosis During Pregnancy

Latest Cystic Fibrosis News and Research

Enterprise Therapeutics doses first person with cystic fibrosis in Phase 2 trial for novel therapy ETD001

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of those suffering from respiratory disease, today announced dosing of the first person with cystic fibrosis (pwCF) in its Phase 2a trial of ETD001.

24 Jul 2024

Cystic fibrosis drug reduces hyper-inflammation in COVID-19 pneumonia patients

A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe COVID-19 pneumonia and could be used to treat other respiratory infections, according to clinical trial results from researchers at UCL, UCLH and the Francis Crick Institute.

18 Jul 2024

One-time prime editing targets common genetic cause of cystic fibrosis

Researchers optimized prime editing for the efficient correction of the cystic fibrosis transmembrane conductance regulator F508del mutation in human airway epithelial cells, achieving high correction efficiencies and functional restoration with minimal off-target effects.

15 Jul 2024

UQ study offers insights into how Haemophilus influenzae manipulates the immune system

Researchers from The University of Queensland have identified how a common bacterium is able to manipulate the human immune system during respiratory infections and cause persistent illness.

12 Jul 2024

Prime editing offers promising path to permanent treatment for cystic fibrosis

Cystic fibrosis is one of the most common genetic disorders, causing thick mucus build-up in the lungs and other parts of the body, breathing problems, and infection.

11 Jul 2024

Smartphone-based behavioral therapy leads to improvements for patients with fibromyalgia

New research led by the University of Cincinnati and Swing Therapeutics found that a self-guided smartphone-based behavioral therapy led to significant improvements for patients with fibromyalgia.

8 Jul 2024

Small molecule discovery offers hope for treatment of Angelman syndrome

Angelman syndrome is a rare genetic disorder caused by mutations in the maternally-inherited UBE3A gene and characterized by poor muscle control, limited speech, epilepsy, and intellectual disabilities.

8 Jul 2024

Phages use selfish DNA to outmaneuver competitors

Curious bits of DNA tucked inside genomes across all kingdoms of life historically have been disregarded since they don't seem to have a role to play in the competition for survival.

5 Jul 2024

Enterprise Therapeutics appoints Dr Renu Gupta as Chief Medical Officer and Dr Janet Hammond as Non-Executive Director

Appointments bring additional respiratory and late clinical-stage drug development experience as Company commences Phase 2a clinical trial of its lead asset.

From Enterprise Therapeutics Ltd 17 Jun 2024

Open-ILD: Pioneering stem cell research to combat interstitial lung disease

Imagine a world where breathing is a luxury and a cough marks the sound of an inner battle. Interstitial Lung Disease (ILD), a condition characterised by inflammation and fibrosis, is a major cause of severe respiratory illness and can occur in children.

13 Jun 2024

Biden’s on target about what repealing ACA would mean for preexisting condition protections

President Joe Biden's reelection campaign wants voters to contrast his record on health care policy with his predecessor's.

13 Jun 2024

Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in the Journal of Cystic Fibrosis1.

12 Jun 2024

Study uncovers two types of dysbiosis in cystic fibrosis

Chronic lung diseases are often accelerated and exacerbated by polymicrobial infections. An international study team led by MedUni Vienna has identified two types of these so-called dysbioses in cystic fibrosis.

11 Jun 2024

Efficient whole-gene insertions can be achieved with improved gene-editing technology

Scientists at the Broad Institute of MIT and Harvard have improved a gene-editing technology that is now capable of inserting or substituting entire genes in the genome in human cells efficiently enough to be potentially useful for therapeutic applications.

10 Jun 2024

Multiple general anesthesia exposure does not compromise brain function in young children, study finds

A University of Queensland-led study has found multiple doses of anesthetics do not compromise brain function in young children.

10 Jun 2024

Innovative sweat monitoring device enables non-invasive health monitoring

Sweat contains biomarkers that can monitor various health conditions, from diabetes to genetic disorders. Sweat sampling, unlike blood collection, is preferred by users due to its painless nature.

28 May 2024

Scientists uncover protein folding secrets through sound

By converting their data into sounds, scientists discovered how hydrogen bonds contribute to the lightning-fast gyrations that transform a string of amino acids into a functional, folded protein.

21 May 2024

Understanding public perception of polygenic embryo screening for IVF

Three out of four U.S. adults support the use of emerging technologies that estimate a future child's likelihood of developing health conditions influenced by multiple genes -; such as diabetes, heart disease, and depression -; before an embryo is implanted during in vitro fertilization (IVF), according to a new public opinion survey led by researchers at Harvard Medical School.

15 May 2024

Study sheds light on challenges faced by caregivers of children with genetic conditions

When it comes to improving the lives of children with genetic conditions, medical research often focuses solely on the children. But there is an equally important population in need of research that a faculty member at the University of Colorado Department of Medicine is highlighting -; the caregivers.

10 May 2024

Innovative methodologies for investigating intestinal mucus properties and response

As much as we might not want to think about it, mucus is everywhere in our bodies. It coats our airways and our digestive systems and serves as a first line of defense against pathogens, a habitat for our microbiomes, and a conveyor belt for our insides to keep everything moving smoothly.

7 May 2024